Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Beijing Biotech
Orano Med LLC
Filamon LTD
Essen Biotech
Essen Biotech
Sapience Therapeutics
Var2 Pharmaceuticals
Mayo Clinic
Merck Sharp & Dohme LLC
Massive Bio, Inc.
Incyte Corporation
Taiho Oncology, Inc.
Novartis
AVM Biotechnology Inc
LigaChem Biosciences, Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
SK Life Science, Inc.